-
Zynerba Redirects Resources After ZYN001 Study Fails To Meet Top-Line Results
Thursday, July 5, 2018 - 9:09am | 254Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares plunged premarket Thursday after the company ended a clinical study for a tetrahydrocannabinol patch. What Happened The Phase 1 study for the ZYN001 patch did not achieve targeted top-line results, Zynerba said in a statement. Why It...
-
The Numbers On Zynerba: 25% Odds Of Success, Potential For 100% Upside
Tuesday, August 1, 2017 - 3:55pm | 319Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), which specializes in transdermal synthetic cannabinoid treatments, has a 25-percent probability for success in its treatment of adult epilepsy, an analyst said Tuesday. Cantor Fitzgerald analyst Elemer Piros said there were no surprises in the Q2 results...
-
What Analysts Expect For Zynerba's Upcoming Wave Of Data
Tuesday, August 1, 2017 - 2:00pm | 414Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported Tuesday its second-quarter results along with a series of updates concerning ongoing clinical trials and when investors can expect top-line data. Zynerba was expected to release phase 2 STAR 1 trial data of its ZYN002 for the treatment of adult...
-
Catalysts Growing Like Weeds For Zynerba Next Quarter
Tuesday, May 9, 2017 - 3:26pm | 372Despite confirming third-quarter catalysts and progress throughout its development pipeline, Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)’s first-quarter financial report didn’t impress investors. The company conceded an 8.3-percent stock decline Tuesday even as it boasts a 22-percent...
-
Exclusive: Zynerba CEO Talks Election, Balance Sheet And Huge Osteoarthritis Market Potential
Friday, November 11, 2016 - 10:54am | 534Benzinga recently had the chance to speak with Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) CEO Armando Anido about the impact the U.S. election will have on the company, the potential of Zynerba’s two main drug candidates and the health of Zynerba’s balance sheet. The Election's...